Skip to content

Choline C-11

FDA-approved product (injectable, intravenous), marketed as Choline C-11.

Registered studies
27
Lab records
2
Pathogens at ≥40%
0 of 4

Chemical structure

Chemical structure of Choline C-11
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Prostate adenocarcinoma
  • Prostate cancer

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

FDA pharmacologic class
Radioactive Diagnostic Agent FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

No supported pathogen reaches ≥40% AI-predicted activity for Choline C-11, so it is not among the repurposing candidates. Its predictions are shown below.

AI-predicted activity

AI prediction · nothing measured
  • MRSA11.1% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • E. coli5.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • K. pneumoniae5.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis17.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

27registered studies name this medicine, for any condition. See them below.

Experimental

  • MRSA: measured active in 0 of 1 lab record
  • E. coli: measured active in 0 of 1 lab record
Show the 2 laboratory records, with sources

Loading records…

“Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-3.2 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-3.8 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-3.3 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-3.3 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Choline C-11 with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Diagnostic Performance of [11C]Choline PET/CT In the Preoperative Assessment of Primary Hyperparathyroidism

    NCT06647966 · start 2025-01

    Registered record
    Registry ID
    NCT06647966
    Conditions
    Primary Hyperparathyroidism
    Interventions
    PET/CT
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Not yet recruiting
    Start
    2025-01
    Completion
    2025-12
    Enrolment
    200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPrimary Hyperparathyroidism
    InterventionPET/CT
    PhaseNot recorded
    Registry statusNot yet recruiting
  • Characterizing LAM With 11C-Choline PET/CT

    NCT05087134 · start 2021-11

    Registered record
    Registry ID
    NCT05087134
    Conditions
    Lymphangioleiomyomatosis
    Interventions
    11C-Choline
    Study type
    INTERVENTIONAL
    Phase
    Early phase 1
    Registry status
    Unknown
    Start
    2021-11
    Completion
    2023-09
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLymphangioleiomyomatosis
    Intervention11C-Choline
    PhaseEarly phase 1
    Registry statusUnknown
  • [Al18F]PSMA137 PET/CT Imaging for PSMA-Positive Cancer Patients

    NCT04693169 · start 2021-01-15

    Registered record
    Registry ID
    NCT04693169
    Conditions
    Prostate Cancer
    Interventions
    11C-Choline
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2021-01-15
    Completion
    2024-12-12
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer
    Intervention11C-Choline
    PhaseNot applicable
    Registry statusUnknown
  • PSMA Specific [68Ga]-P137 Peptide Probe for PET Imaging in Prostate Cancer

    NCT04560725 · start 2020-10-22

    Registered record
    Registry ID
    NCT04560725
    Conditions
    Prostate Cancer
    Interventions
    11C-Choline
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2020-10-22
    Completion
    2024-12-01
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer
    Intervention11C-Choline
    PhaseNot applicable
    Registry statusUnknown
  • PSMA and C-11 Choline PET in Patients With Biochemical Recurrence of Prostate Cancer

    NCT03768349 · start 2019-01-03

    Registered record
    Registry ID
    NCT03768349
    Conditions
    Prostate Cancer
    Interventions
    Ga-68 PSMA11; F-18 PSMA 1007
    Study type
    INTERVENTIONAL
    Phase
    Early phase 1
    Registry status
    Completed
    Start
    2019-01-03
    Completion
    2021-07-21
    Enrolment
    250

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer
    InterventionGa-68 PSMA11; F-18 PSMA 1007
    PhaseEarly phase 1
    Registry statusCompleted
  • Staging Prostate Cancer With Hybrid C11-Choline PET/MR and mpMRI

    NCT03404648 · start 2017-11-01

    Registered record
    Registry ID
    NCT03404648
    Conditions
    Prostate Adenocarcinoma
    Interventions
    C-11 choline PET tracer; Gadobutrol; PET/MR scanner
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2017-11-01
    Completion
    2020-01-23
    Enrolment
    19

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Adenocarcinoma
    InterventionC-11 choline PET tracer; Gadobutrol; PET/MR scanner
    PhasePhase 3
    Registry statusCompleted
  • Molecular PET/MR Imaging in Vivo Validation of Biomarker for Human Prostate Cancer

    NCT03451812 · start 2017-01-01

    Registered record
    Registry ID
    NCT03451812
    Conditions
    Prostate Adenocarcinoma
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2017-01-01
    Completion
    2019-12-31
    Enrolment
    120

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Adenocarcinoma
    InterventionNot recorded
    PhaseNot recorded
    Registry statusUnknown
  • Assessing 11C-Choline (11C-CH) PET to Distinguish True Tumor Progression From Pseudoprogression in High-grade Gliomas

    NCT02849171 · start 2016-07

    Registered record
    Registry ID
    NCT02849171
    Conditions
    Brain Cancer
    Interventions
    PET scan; C-Choline
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2016-07
    Completion
    2022-05-06
    Enrolment
    8

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBrain Cancer
    InterventionPET scan; C-Choline
    PhaseNot applicable
    Registry statusCompleted
  • 11C-choline PET/CT Based Helical Tomotherapy as Innovative Treratment Approach for Bone Metastases in Prostate Cancer Patients.

    NCT06179706 · start 2015-10-27

    Registered record
    Registry ID
    NCT06179706
    Conditions
    Prostate Cancer
    Interventions
    11C-choline PET/CT
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2015-10-27
    Completion
    2015-11-25
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer
    Intervention11C-choline PET/CT
    PhaseNot recorded
    Registry statusCompleted
  • Radiation Treatment of Lymph Node Recurrence From Prostate Cancer : is 11C-choline PET/CT Predictive of Survival Outcomes?

    NCT06170164 · start 2015-10-08

    Registered record
    Registry ID
    NCT06170164
    Conditions
    Prostate Cancer
    Interventions
    Diagnostic accuracy
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2015-10-08
    Completion
    2015-11-25
    Enrolment
    68

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer
    InterventionDiagnostic accuracy
    PhaseNot recorded
    Registry statusCompleted
  • Carbon-11 Labeled Sarcosine in Prostate Cancer

    NCT02462447 · start 2015-06

    Registered record
    Registry ID
    NCT02462447
    Conditions
    Prostate Cancer
    Interventions
    11C-sarcosine; 11C-choline
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2015-06
    Completion
    2017-02-08
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer
    Intervention11C-sarcosine; 11C-choline
    PhaseNot recorded
    Registry statusCompleted
  • 11C- and 18F-Choline PET/MR Imaging for Prostate Cancer

    NCT02397408 · start 2015-04-09

    Registered record
    Registry ID
    NCT02397408
    Conditions
    Prostate Cancer
    Interventions
    Carbon C 11 Choline; Fluorine F 18 Choline; Positron Emission Tomography (PET) / Magnetic Resonance Imaging (MRI)
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2015-04-09
    Completion
    2015-06-30
    Enrolment
    18

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer
    InterventionCarbon C 11 Choline; Fluorine F 18 Choline; Positron Emission Tomography (PET) / Magnetic Resonance Imaging (MRI)
    PhasePhase 2
    Registry statusCompleted
  • 11C-Choline PET/CT and DWI MRI for Response Assessment of HCC Candidate to TARE

    NCT02519075 · start 2015-04

    Registered record
    Registry ID
    NCT02519075
    Conditions
    Hepatocarcinoma
    Interventions
    No intervention
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2015-04
    Completion
    2018-12
    Enrolment
    14

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatocarcinoma
    InterventionNo intervention
    PhaseNot recorded
    Registry statusCompleted
  • A Retrospective Analysis of the Diagnostic Performance of 11C-choline PET/CT in Primary Hyperparathyroidism

    NCT04608253 · start 2015-01-01

    Registered record
    Registry ID
    NCT04608253
    Conditions
    Primary Hyperparathyroidism; Primary Hyperparathyroidism Due to Adenoma
    Interventions
    11C-choline PET/CT
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2015-01-01
    Completion
    2020-08-01
    Enrolment
    36

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPrimary Hyperparathyroidism; Primary Hyperparathyroidism Due to Adenoma
    Intervention11C-choline PET/CT
    PhaseNot recorded
    Registry statusCompleted
  • The Role of C-11 Choline PET in Patients With Prostate Cancer

    NCT02852122 · start 2015-01

    Registered record
    Registry ID
    NCT02852122
    Conditions
    Latent Cancer Prostate
    Interventions
    C-11 choline
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2015-01
    Completion
    2016-12
    Enrolment
    54

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLatent Cancer Prostate
    InterventionC-11 choline
    PhaseNot applicable
    Registry statusCompleted